Market Design

I'll post market design related news and items about repugnant markets. See also my Stanford profile. I have a general-interest book on market design: Who Gets What--and Why The subtitle is "The new economics of matchmaking and market design."

Showing posts with label hepatitis. Show all posts

Friday, September 22, 2023

Support for hepatitis C human challenge studies, in The Lancet Gastroenterology & Hepatology

›

Here's a call for action, in The Lancet Gastroenterology & Hepatology: Joint statement in support of hepatitis C human challenge st...

Saturday, August 26, 2023

Challenge trials for a Hepatitis C vaccine

›

The Journal Clinical Infectious Diseases has a special supplement on challenge trials (human infection trials) of a Hep C vaccine (now tha...

Monday, May 15, 2023

Eliminating Hepatitis C, now that there's a cure (even though it's expensive)

›

There's growing discussion about eliminating Hep C in the U.S., doing appropriate deals with the two drug companies whose patents still...

Monday, March 21, 2016

Transplanting kidneys that are infected with hepatitis C (to uninfected patients) or HIV (to already infected patients) to ease the organ shortage

›

Two stories, one on Hep C kidneys to uninfected patients, another on HIV kidneys to patients already infected with HIV. Here's the fi...

Wednesday, August 13, 2014

Good news about a dangerous disease (hepatitis), at a high price

›

The good news is that there's a cure. The bad news is that it isn't cheap. Here's the NY Times headline on what is proving to b...

›

Home

View web version

About Me

Al Roth

View my complete profile